PharmaEssentia Corporation
6446
Classificação em ações
#1439
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Preço da ação
$36.89
Valor de mercado
$15.25B
Variação (1 dia)
-1.28%
Variação (1 ano)
144.12%
País
TW
Negociar PharmaEssentia Corporation (6446)
Categoria
Healthcare
Lucros da PharmaEssentia Corporation (6446)
Lucros em Jun 2026 TTM: $284.95M
De acordo com os últimos relatórios financeiros da PharmaEssentia Corporation, os ganhos atuais da empresa são de $284.95M. Em 2023, a empresa teve ganhos de $-32.16M, um aumento em relação a aos ganhos de 2022, que foram de $-60.07M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da PharmaEssentia Corporation de 2010 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2026 (TTM) | $284.95M | 212.31% |
| 2024 | $91.24M | -383.66% |
| 2023 | $-32.16M | -46.45% |
| 2022 | $-60.07M | -40.77% |
| 2021 | $-101.42M | 46.26% |
| 2020 | $-69.34M | 146.30% |
| 2019 | $-28.15M | -17.15% |
| 2018 | $-33.98M | 15.54% |
| 2017 | $-29.41M | 12.91% |
| 2016 | $-26.05M | 0.49% |
| 2015 | $-25.92M | -3.64% |
| 2014 | $-26.90M | 35.45% |
| 2013 | $-19.86M | 125.31% |
| 2012 | $-8.81M | 31.09% |
| 2011 | $-6.72M | 17.15% |
| 2010 | $-5.74M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 519.26% |
IN
|
